ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Sangart, Inc. Initiates Dosing In Phase II Study Of Hemospan(R) In Chronic Critical Limb Ischemia
Sangart, Inc., a privately held
biopharmaceutical company focused on the research, development and
commercialization of oxygen transport agents, announced that it has
started testing its lead product, Hemospan(R), in a Phase II clinical study
involving chronic critical limb ischemia (CCLI) patients.
The single-blind, placebo-controlled study at the Karolinska Institute
in Stockholm, Sweden is designed to evaluate the safety and efficacy of
Hemospan in patients suffering from CCLI, a debilitating condition that
results from severely limited blood circulation to the legs. The primary
endpoint is tissue oxygenation measured noninvasively.
The goal of this study is to demonstrate that Hemospan can increase
oxygen supply to severely compromised tissue, conclusively establishing it
as an 'oxygen-carrying plasma expander,'" said Dr. Robert Winslow,
Chairman, President and CEO of Sangart.
Hemospan is a hemoglobin-based oxygen transport agent designed to serve
as an oxygen therapeutic and as an alternative to blood transfusions. A key
property of Hemospan is its high oxygen affinity which results in targeted
oxygen delivery to tissues at risk of oxygen deprivation.
About Sangart
Sangart is a privately held biopharmaceutical company focused on the
research, development and commercialization of medical products designed
for use as oxygen transport agents.
Dr. Robert Winslow, a world-renowned authority in the field of oxygen
transport, founded Sangart in 1998. In the two decades prior to founding
Sangart, Dr. Winslow and his colleagues studied and defined mechanisms of
oxygen transport by cell-free hemoglobin solutions, funded by competitive
grants from the National Institutes of Health and the Department of
Defense. The counterintuitive discoveries by Dr. Winslow's group on the
effective action of oxygen transport agents have been patented and
published in numerous scientific articles. From this experience, Sangart's
lead product, Hemospan(R), was designed using unique polyethylene glycol
conjugation to create a hemoglobin-based product that is intended to serve
as an oxygen therapeutic and as an alternative to donated blood.
The key breakthroughs in the development of Hemospan were the
understanding of the mechanisms of vasoconstriction caused by cell-free
hemoglobin and the development of simplified production methods that are
designed to make the final product commercially viable.
Sangart's corporate headquarters are in San Diego, California. To learn
more about Sangart, please visit the company's website at http://www.sangart.com.
Sangart, Inc.
http://www.sangart.com
Sangart, Inc iniþiazã Dozarea În faza a II-Studiul Hemospan (R) cronice critice corporale ischemie - Sangart, Inc. Initiates Dosing In Phase II Study Of Hemospan(R) In Chronic Critical Limb Ischemia - articole medicale engleza - startsanatate